|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease显示文摘瞄准:为了调查可溶的被触发的可能的角色,受体在煽动性的肠疾病(IBD ) 的致病在骨髓的上表示了 cells-1 (sTREM-1 ) 。方法:58 个病人被注册;十九个健康志愿者用作控制;8 个病人与 Crohn 的疾病被诊断,并且 31 与 ulcerative。有 Crohn 的疾病和 ulcerative 的病人的临床、内视镜的活动索引分别地被估计。在承认之上,血被取样;sTREM-1 和 TNFalpha 被 thiobarbitourate 试金被免疫分析和 malondialdehyde (MDA ) 测量,在通过一个 HPLC 系统的经过以后。结果:控制,有 Crohn 的疾病的病人和有 ulcerative 的病人的 TNFalpha 的中部的 +/- SE 是 6.02 +/- 3.94, 7.98 +/- 5.08 (P = NS 对控制) ,并且 8.45 +/- 4.15 ng/L (P = 0.018 对控制) 分别地。sTREM-1 的各自的价值是 53.31 +/- 32.93, 735.10 +/- 197.17 (P = 0.008 对控制) 并且 435.82 +/- 279.71 ng/L (P = 0.049 对控制) 。sTREM-1 断然与 Crohn 的疾病活动索引和 ulcerative 的临床、内视镜的活动索引被相关(P = 0.002, 0.001 和 0.009,分别地) 。有 ulcerative 的病人的 sTREM-1 断然与 TNFalpha 被相关(P = 0.001 ) 。结论:sTREM-1 似乎在与肠粘膜的炎性反应的度的关联在 IBD 作为一个新奇调停人表现。 | Michalis Tzivras Vassilios Koussoulas Evangelos J Giamarellos-Bourboulis Dimitrios Tzivras Thomas Tsaganos Pantelis Koutoukas Helen Giamarellou Athanasios Archimandritis | 2006 | World Journal of Gastroenterology2006，12，21： | 17 |
| 2 | Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C显示文摘Classical interferon-alpha has been shown to be correlated with the development of a variety of autoimmune disorders. A 38 year-old female patient developed simultaneously diabetic ketoacidosis and hyperthyroidism 5 mo following initiation of treatment with pegylated interferon-α and ribavirin for chronic hepatitis C. High titers of glutamic acid decarboxylase, antinuclear and thyroid (thyroid peroxidase and thyroglobulin) antibodies were detected. Antiviral treatment was withdrawn and the patient was treated with insulin for insulin-dependent diabetes mellitus and propranolol for hyperthyroidism. Twelve months after cessation of pegylated interferon-α therapy the patient was euthyroid without any medication but remained insulin-dependent. | Aspasia S Soultati Spyridon P Dourakis Alexandra Alexopoulou Melanie Deutsch Athanasios J Archimandritis | 2007 | World Journal of Gastroenterology2007，13，8： | 15 |
| 3 | Current treatment indications and strategies in chronic hepatitis B virus infection显示文摘The optimal approach to the management of several marginal cases with chronic hepatitis B virus (HBV) infection is controversial. Serum HBV DNA and ami-notransferase levels, and the degree of necroinflammation and fibrosis determine the therapeutic decisions. All patients with elevated aminotransferase (> twice the upper limit of normal) and serum HBV DNA above 20 000 IU/mL should be treated. Liver biopsy is important for therapeutic decisions in cases with mild aminotransferase elevations and serum HBV DNA below 20 000 IU/mL. Chronic HBV patients who do not receive treatment should be followed for life. There are seven agents licensed for chronic hepatitis B: standard and pegylated interferon-alpha, lamivudine, adefovir, entecavir, telbivudine and tenofovir. One-year courses with pegylated interferon-alpha induce sustained off-therapy remission in 30%-32% of patients with HBeAg-positive chronic hepatitis B and in a smaller proportion of patients with HBeAg-negative chronic hepatitis B. Oral antivirals achieve initial on-therapy responses in the majority of patients, but are intended as long-term therapies. Viral suppression has favourable effects on patients' outcome and modifies the natural course of the disease. Viral resistance, however, is the major drawback of long-term oral antiviral therapy. Lamivudine monotherapy is associated with the highest and ente-cavir monotherapy with the lowest resistance rate so far. There has been no resistance to tenofovir, but afteronly 18 mo of treatment to date. The optimal first-line anti-HBV therapy with the best long-term cost/benefit ratio remains unclear. If oral antiviral agents are used, compliance should always be ascertained and HBV DNA levels should be regularly tested. | George V Papatheodoridis Spilios Manolakopoulos Athanasios J Archimandritis | 2008 | World Journal of Gastroenterology2008，14，45： | 7 |
| 4 | Cholangiocarcinoma:A 7-year experience at a single center in Greece显示文摘AIM: To evaluate survival rate and clinical outcome of cholangiocarcinoma.METHODS: The medical records of 34 patients with cholangiocarcinoma,seen at a single hospital between the years 1999-2006,were retrospectively reviewed.RESULTS: Thirty-four patients with a median age of 75 years were included.Seventeen (50%) had painless jaundice at presentation.Sixteen (47.1%) were perihilar,15 (44.1%) extrahepatic and three (8.8%) intrahepatic.Endoscopic retrograde cholangiography (ERCP) and/or magnetic resonance cholangiography (MRCP) were used for the diagnosis.Pathologic confirmation was obtained in seven and positive cytological examination in three.Thirteen patients had co-morbidities (38.2%).Four cases were managed with complete surgical resection.All the rest of the cases (30) were characterized as non-resectable due to advanced stage of the disease.Palliative biliary drainage was performed in 26/30 (86.6%).The mean follow-up was 32 mo (95% CI,20-43 mo).Overall median survival was 8.7 mo (95% CI,2-16 mo).The probability of 1-year,2-year and 3-year survival was 46%,20% and 7%,respectively.The survival was slightly longer in patients who underwent resection compared to those who did not,but this difference failed to reach statistical significance.Patients who underwent biliary drainage had an advantage in survival compared to those who did not (probability of survival 53% vs 0% at 1 year,respectively,P = 0.038).CONCLUSION: Patients with cholangiocarcinoma were usually elderly with co-morbidities and/or advanced disease at presentation.Even though a slight amelioration in survival with palliative biliary drainage was observed,patients had dismal outcome without resection of the tumor. | Alexandra Alexopoulou Aspasia Soultati Spyros P Dourakis Larissa Vasilieva Athanasios J Archimandritis | 2008 | World Journal of Gastroenterology2008，14，40： | 3 |
| 5 | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection显示文摘 | George V Papatheodoridis Spilios Manolakopoulos Geoffrey Dusheiko Athanasios J Archimandritis | 2008 | The Lancet Infectious Diseases2008，，3： | 2 |
| 6 | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection显示文摘 | George V Papatheodoridis Spilios Manolakopoulos Geoffrey Dusheiko Athanasios J Archimandritis | 2008 | The Lancet Infectious Diseases2008，，3： | 2 |
| 7 | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection显示文摘 | George V Papatheodoridis Spilios Manolakopoulos Geoffrey Dusheiko Athanasios J Archimandritis | 2008 | The Lancet Infectious Diseases2008，，3： | 1 |
| 8 | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection显示文摘 | George V Papatheodoridis Spilios Manolakopoulos Geoffrey Dusheiko Athanasios J Archimandritis | 2008 | The Lancet Infectious Diseases2008，，3： | 1 |
| 9 | Predicting utility of a model for end stage liver disease in alcoholic liver disease显示文摘瞄准:作为短术语(30 d 和 90 d ) 的预言者为结束阶段肝疾病验证 Maddrey 判别式函数分数和模型的统计实用程序在有含酒精的肝炎并且到的病人的死亡与含酒精的肝炎在临床的特征和病人的实验室变量之中估计预示的因素。方法:有含酒精的肝炎的诊断的 34 个病人承认从 2000 ~ 2005 的雅典的大学医院在当前的回顾的学习被估计,统计分析被进行到 Hippokration。结果:30-d 和 90-d 死亡率在 5.9% 点被报导(2/34 ) 并且 14.7%(5/34 ) 分别地。重要关联为结束阶段肝疾病为模型被表明( P30 = 0.094 , P90 = 0.046 )并且 Maddrey 判别式功能分数( P30 = 0.033 , P90 = 0.038 )与 30-d 和 90-d 死亡而一个重要协会也为丙氨酸 aminotransferase 被建立( P = 0.057 ),血纤维蛋白降级产品( P = 0.048 )并且C反应的蛋白质( P = 0.067 )与 90-d 死亡。为 30-d 死亡,在曲线下面的区域是 0.969 (95%CI:0.902-1.036, P = 0.028 ) 为为结束阶段肝疾病 20 和 0.984 的模型(95%CI:0.942-1.027, P = 0.023 ) 为 Maddrey 判别式功能分数与最佳割掉 30.5 的点(敏感 1,特性 0.937 ) 并且 108.68 (敏感 1,特性 0.969 ) 分别地。因此,为 90-d 死亡,在曲线下面的区域是 0.762 (95%CI:0.559-0.965, P = 0.065 ) 为为结束阶段肝疾病 20 和 0.752 的模型(95%CI:0.465-1.038, P = 0.076 ) 为 Maddrey 判别式功能分数与最佳割掉 19 的点(敏感 0.6,特性 0.6 ) 并且 92 (敏感 0.6,特性 0.946 ) 分别地。为不同分数范畴的观察 Kaplan Meier 幸存率与木头等级测试和更高的分数相比价值与更低的幸存被相关。结论:为结束阶段肝疾病和 Maddrey 判别式功能分数的模型的相等被当前的学习暗示,由阴谋的接收装置起作用的曲线和估计的幸存率验证了。90-d 死亡的独立预言者也被验证了的 C 反应的蛋白质,血纤维蛋白降级产品和丙氨酸 aminotransferase 的一个统计上重要的实用程序。 | Aspasia S Soultati Spyridon P Dourakis Alexandra Alexopoulou Melanie Deutsch Larissa Vasilieva Athanasios J Archimandritis | 2006 | World Journal of Gastroenterology2006，12，25： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员